A SMART Platform For Scalable Biotherapeutic Development: cDNA To 200L Single Use Stirred Tank Bioreactor

Establishing a platform for developing and manufacturing therapeutic proteins will eliminate the bottleneck between cell line development and tech transfer. The Celltheon SMARTTM Technology Platform in combination with Pall Biotech’s manufacturing equipment accelerates time from cDNA to pilot scale with a pre-defined fed-batch and downstream processing platform for monoclonal antibodies and difficult to express therapeutic proteins In this case study, Celltheon demonstrates a workflow established to develop an RCB followed by scale-up and reproducible product quality from bench to pilot scale in the 200 L Allegro STR single-use bioreactor.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online